3 active not recruiting, 2 completed, 1 approved for marketing, 1 recruiting. 4 Phase 1, 4 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Active not recruiting 1, Completed 1, Recruiting 1, Terminated 1 |
| Phase 2 | 4 | Active not recruiting 1, Completed 1, Recruiting 1, Withdrawn 1 |
| Phase 3 | 2 | Active not recruiting 2 |
Follow Merus B.V.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer Petosemtamab + Pembrolizumab - Lung Cancer - Non Small Cell Squamous, Lung Cancer - Non Small Cell Non-Squamous | Phase 2 | Withdrawn | Merus B.V. | 2026-03-27 | 2026-08-13 | |
| A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) Petosemtamab, Pembrolizumab - Head and Neck Squamous Cell Carcinoma | Phase 3 | Active not recruiting | Merus B.V. | 699 | 2024-09-25 | 2026-09-25 |
| A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2) Petosemtamab, Investigator's Choice - Head and Neck Squamous Cell Carcinoma | Phase 3 | Active not recruiting | Merus B.V. | 621 | 2024-06-25 | 2026-10-19 |
| Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination MCLA-129, Osimertinib, Chemotherapy - Non-Small Cell Lung Cancer Metastatic, Gastric Cancer | Phase 1 / Phase 2 | Active not recruiting | Merus B.V. | 194 | 2021-04-28 | 2026-02-19 |
| A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies MCLA-145, Pembrolizumab (Keytruda) - Advanced Cancer, Solid Tumor, Adult | Phase 1 | Completed | Merus B.V. | 72 | 2019-05-08 | 2024-12-11 |
| A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors MCLA-158, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI - Advanced/Metastatic Solid Tumors, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | Merus B.V. | 560 | 2018-05-02 | 2026-10-20 |
| MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer. Zenocutuzumab, Trastuzumab, Vinorelbine - Breast Cancer Metastatic | Phase 2 | Completed | Merus B.V. | 105 | 2018-01-15 | 2024-03-07 |
| MCLA-117 in Acute Myelogenous Leukemia MCLA-117 bispecific antibody - Acute Myelogenous Leukemia, Acute Myeloid Leukemia | Phase 1 | Terminated | Merus B.V. | 80 | 2016-04-01 | 2025-04-06 |
| Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor MCLA-128 - NRG1 Fusion, Pancreatic Cancer | Approved for marketing | Merus B.V. | 2025-05-20 |
Squamous Cell Carcinoma of Head and Neck (4) · Colorectal Neoplasms (3) · Head and Neck Neoplasms (3) · Stomach Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Cholangiocarcinoma (1) · Esophageal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Laryngeal Diseases (1) · Lethal Congenital Contracture Syndrome 2 (1) · Leukemia, Myeloid, Acute (1) · Lung Neoplasms (1) · Lymphoma, B-Cell (1)
pembrolizumab (4) · zenocutuzumab (2) · Anastrozole (1) · CD3 Complex (1) · Drug Therapy (1) · Folfox protocol (1) · Fulvestrant (1) · Letrozole (1) · Trastuzumab (1) · Vinorelbine (1) · exemestane (1) · osimertinib (1)
Netherlands (8) · United States (8) · Belgium (7) · France (7) · Spain (7) · Italy (6) · South Korea (4) · United Kingdom (4) · Australia (3) · Germany (3) · Portugal (3) · Argentina (2) · Brazil (2) · Canada (2) · Chile (2)
Ernesto Wasserman, MD (1) · Gianluca Laus, MD (1) · Jorge Cortes, MD, PhD (1) · Silke Thiele, MD (1)
2017 (2), 2023 (2), 2015 (1), 2018 (1)